8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-Based Scaffolds en Route to Donepezil-Like Compounds

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An unsubstituted 2-hydroxyphenylbenzimidazole has recently been included as a scaffold in a series of hybrids (including the hit compound PZ1) based on the framework of the acetylcholinesterase (AChE) inhibitor Donepezil, which is a new promising multi-target ligand in Alzheimer’s disease (AD) treatment. Building upon these findings, we have now designed and completed the whole synthesis of PZ1 in the so-called deep eutectic solvents (DESs), which have emerged as an unconventional class of bio-renewable reaction media in green synthesis. Under optimized reaction conditions, the preparation of a series of 2-hydroxyphenylbenzimidazole-based nuclei has also been perfected in DESs, and comparison with other routes which employ toxic and volatile organic solvents (VOCs) provided. The functionalization of the aromatic ring can have implications on some important biological properties of the described derivatives and will be the subject of future studies of structure-activity relationships (SARs).

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular mechanisms of neurodegeneration in Alzheimer's disease.

          Alzheimer's disease (AD) is characterized by cognitive impairment, progressive neurodegeneration and formation of amyloid-beta (Abeta)-containing plaques and neurofibrillary tangles composed of hyperphosphorylated tau. The neurodegenerative process in AD is initially characterized by synaptic damage accompanied by neuronal loss. In addition, recent evidence suggests that alterations in adult neurogenesis in the hippocampus might play a role. Synaptic loss is one of the strongest correlates to the cognitive impairment in patients with AD. Several lines of investigation support the notion that the synaptic pathology and defective neurogenesis in AD are related to progressive accumulation of Abeta oligomers rather than fibrils. Abnormal accumulation of Abeta resulting in the formation of toxic oligomers is the result of an imbalance between the levels of Abeta production, aggregation and clearance. Abeta oligomers might lead to synaptic damage by forming pore-like structures with channel activity; alterations in glutamate receptors; circuitry hyper-excitability; mitochondrial dysfunction; lysosomal failure and alterations in signaling pathways related to synaptic plasticity, neuronal cell and neurogenesis. A number of signaling proteins, including fyn kinase; glycogen synthase kinase-3beta (GSK3beta) and cyclin-dependent kinase-5 (CDK5), are involved in the neurodegenerative progression of AD. Therapies for AD might require the development of anti-aggregation compounds, pro-clearance pathways and blockers of hyperactive signaling pathways.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Deep-eutectic solvents playing multiple roles in the synthesis of polymers and related materials.

            The aim of this review is to provide an exposition of some of the most recent applications of deep-eutectic solvents (DESs) in the synthesis of polymers and related materials. We consider that there is plenty of room for the development of fundamental research in the field of DESs because their compositional flexibility makes the number of DESs susceptible of preparation unlimited and so do the range of properties that DESs can attain. Ultimately, these properties can be transferred into the resulting materials in terms of both tailored morphologies and compositions. Thus, interesting applications can be easily envisaged, especially in those fields in which the preparation of high-tech products via low cost processes is critical. We hope that the preliminary work surveyed in this review will encourage scientists to explore the promising perspectives offered by DESs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Drug development in Alzheimer’s disease: the path to 2025

              The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. In this paper, we discuss the path to 2025, and what is feasible in this time frame given the realities and challenges of AD drug development, with a focus on disease-modifying therapies (DMTs). Under the current conditions, only drugs currently in late Phase 1 or later will have a chance of being approved by 2025. If pipeline attrition rates remain high, only a few compounds at best will meet this time frame. There is an opportunity to reduce the time and risk of AD drug development through an improvement in trial design; better trial infrastructure; disease registries of well-characterized participant cohorts to help with more rapid enrollment of appropriate study populations; validated biomarkers to better detect disease, determine risk and monitor disease progression as well as predict disease response; more sensitive clinical assessment tools; and faster regulatory review. To implement change requires efforts to build awareness, educate and foster engagement; increase funding for both basic and clinical research; reduce fragmented environments and systems; increase learning from successes and failures; promote data standardization and increase wider data sharing; understand AD at the basic biology level; and rapidly translate new knowledge into clinical development. Improved mechanistic understanding of disease onset and progression is central to more efficient AD drug development and will lead to improved therapeutic approaches and targets. The opportunity for more than a few new therapies by 2025 is small. Accelerating research and clinical development efforts and bringing DMTs to market sooner would have a significant impact on the future societal burden of AD. As these steps are put in place and plans come to fruition, e.g., approval of a DMT, it can be predicted that momentum will build, the process will be self-sustaining, and the path to 2025, and beyond, becomes clearer.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Molecules
                Molecules
                molecules
                Molecules
                MDPI
                1420-3049
                28 January 2020
                February 2020
                : 25
                : 3
                : 574
                Affiliations
                [1 ]Dipartimento di Farmacia–Scienze del Farmaco, Università degli Studi di Bari «Aldo Moro», Via E. Orabona 4, I-70125 Bari, Italy; r.sergio2@ 123456studenti.uniba.it (R.S.); f.rinaldo@ 123456studenti.uniba.it (F.R.); l.brunetti2@ 123456studenti.uniba.it (L.B.); filippo.perna@ 123456uniba.it (F.M.P.)
                [2 ]Consorzio C.I.N.M.P.I.S., Via E. Orabona 4, I-70125 Bari, Italy
                [3 ]Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal; masantos@ 123456ist.utl.pt
                Author notes
                [* ]Correspondence: luca.piemontese@ 123456uniba.it (L.P.); vito.capriati@ 123456uniba.it (V.C.); Tel.: +39-080-5442174 (V.C.)
                Author information
                https://orcid.org/0000-0002-7980-5818
                https://orcid.org/0000-0002-7787-6639
                https://orcid.org/0000-0002-8735-8165
                https://orcid.org/0000-0003-4883-7128
                Article
                molecules-25-00574
                10.3390/molecules25030574
                7037276
                32013037
                b174d223-a828-4f3c-8b7c-a8df86a94e0b
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 19 December 2019
                : 27 January 2020
                Categories
                Article

                deep eutectic solvents,2-hydroxyphenylbenzimidazole,alzheimer’s disease

                Comments

                Comment on this article